Jump to main content
Jump to site search
PLANNED MAINTENANCE Close the message box

Scheduled maintenance work on Wednesday 27th March 2019 from 11:00 AM to 1:00 PM (GMT).

During this time our website performance may be temporarily affected. We apologise for any inconvenience this might cause and thank you for your patience.

Issue 5, 2010
Previous Article Next Article

Strategies to prolong the plasma residence time of peptide drugs

Author affiliations


Peptides are an attractive class of molecules for the development of therapeutics because they combine unique properties such as high binding affinity, excellent target specificity, low toxicity and a relatively small mass. However, the short in vivo half-life of peptides which is typically only a few minutes had hampered the development of a larger number of peptide leads into drugs. The main reasons for the fast elimination of peptides from the circulation are enzymatic degradation and/or fast renal clearance. To prolong the half-life of peptides, their proteolytic stability can be improved by chemical modification strategies and the rate of clearance can be reduced by conjugating the peptides to molecules that prevent their elimination through the kidney. In this article we review the latter class of strategies that aims at prolonging the in vivo plasma residence time of peptides. Techniques including peptide drug linkage to large polymers, fusion to long-lived proteins such as albumin or the Fc fragment of immunoglobulin and conjugation to small molecule albumin-binding tags are discussed and the peptide-conjugate half-lives achieved are compared.

Graphical abstract: Strategies to prolong the plasma residence time of peptide drugs

Back to tab navigation

Publication details

The article was received on 15 Jul 2010, accepted on 13 Sep 2010 and first published on 21 Oct 2010

Article type: Review Article
DOI: 10.1039/C0MD00111B
Citation: Med. Chem. Commun., 2010,1, 319-324

  •   Request permissions

    Strategies to prolong the plasma residence time of peptide drugs

    L. Pollaro and C. Heinis, Med. Chem. Commun., 2010, 1, 319
    DOI: 10.1039/C0MD00111B

Search articles by author